Picture
SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare
Free Samples
In Vitro DiagnosticsPOC Diagnostics

PUBLISHER: MarketsandMarkets | PRODUCT CODE: 1725769

Cover Image

PUBLISHER: MarketsandMarkets | PRODUCT CODE: 1725769

ASEAN Point of Care Diagnostics Market by Product (Infectious Disease (TB, Hepatitis, STDs, HAIs), Glucose, Cardiometabolic, Pregnancy, Coagulation), Technology (Lateral Flow Assays, Biochemistry, MDx), End User (Home Care, Hospitals) - Forecast to 2030

PUBLISHED:
PAGES: 334 Pages
DELIVERY TIME: 1-2 business days
REQUEST FREE SAMPLE
REQUEST CUSTOMIZATION
SELECT AN OPTION
PDF (Single User License)
USD 4950
PDF (5-user License)
USD 6650
PDF (Corporate License)
USD 8150
PDF (Global License)
USD 10000

Add to Cart

Description

Table of Contents

List of Tables

The ASEAN point of care diagnostics market is expected to grow from USD 1.08 billion in 2025 to reach USD 1.36 billion in 2030, at a CAGR of 4.7% during the forecast period. Favorable government policies and funding investments drive the demand for Point of Care (POC) testing in the ASEAN region. Governments in these countries are increasingly supporting adopting such technologies to improve health access, reduce costs, and enhance patient outcomes. Through strategic partnerships, research initiatives, and nationwide screening campaigns, ASEAN governments promote using POC technologies to make healthcare accessible, lower costs, and improve patient outcomes. In several developing nations within the region, where health infrastructure is relatively underdeveloped, authorities encourage using POC devices to decentralize laboratory-based diagnostics and expand access to testing. These supportive initiatives are fostering the growth of POC diagnostics and creating new market opportunities for diagnostic firms in the ASEAN region.

Scope of the Report
Years Considered for the Study2024-2030
Base Year2024
Forecast Period2024-2030
Units ConsideredValue (USD billion)
SegmentsProduct, Technology, and End User
Regions coveredVietnam, Laos, Cambodia, Malaysia, Myanmar, Philippines, Singapore, Thailand, Indonesia, and Brunei

"The infectious disease testing products segment is expected to register the highest growth rate in the ASEAN point of care diagnostics market, by product."

Based on product, the ASEAN point of care diagnostics market is segmented into infectious disease testing products, glucose monitoring products, cardiometabolic testing products, coagulation monitoring products, pregnancy & fertility testing products, urinalysis testing products, cancer marker testing products, cholesterol testing products, hematology testing products, fecal occult testing products, drugs-of-abuse testing products, and other POC products. Among them, the infectious disease testing products segment is expected to grow at the highest CAGR, primarily driven by the region's continuous efforts towards enhancing disease surveillance and outbreak control. Recurrent outbreaks of infectious diseases, in addition to the requirement for rapid diagnosis in both urban & rural healthcare facilities, are fueling the demand for effective POC solutions. Additionally, the rapid development of advanced molecular platforms and immunoassays will facilitate the effective and smooth identification of infectious diseases, further expanding adoption among ASEAN countries.

"By technology, the Biochemistry segment accounted for the largest market share in the ASEAN point of care diagnostics market in 2024."

The ASEAN point of care diagnostics market is segmented by technology into lateral flow assays (immunoassays), rapid tests (molecular diagnostics), and biochemistry. In 2024, the Biochemistry segment accounted for the largest share of the market owing to its extensive usability in a variety of routine & essential diagnostic tests such as blood glucose checks, electrolyte analysis, liver function tests, and kidney function tests. The high prevalence of chronic & lifestyle-associated diseases like diabetes, cardiovascular disease, and kidney disorders in the ASEAN countries has also substantially necessitated the need for point-of-care testing solutions based on biochemistry. Moreover, the ease of operation, cost-effectiveness, and shorter turnaround time of biochemistry analyzers make them appropriate for decentralized healthcare environments such as community clinics, primary health centers, and emergency departments. The growing demand for early disease detection & diagnosis has further supported the implementation of biochemistry-based POC solutions in the ASEAN market.

"Vietnam is the fastest-growing market for point of care diagnostics in the ASEAN region"

The ASEAN market for point of care diagnostics is categorized into Vietnam, Laos, Cambodia, Malaysia, Myanmar, Philippines, Singapore, Thailand, Indonesia, and Brunei. Vietnam is expected to grow at the highest CAGR during the forecast period. Vietnam's strong focus on strengthening its primary healthcare network and expanding nationwide screening programs-especially after the COVID-19 pandemic-has significantly increased the adoption of point-of-care diagnostic solutions in public and private healthcare facilities. Additionally, the country is committed to improving the early detection and management of infectious diseases, bolstered by its robust disease surveillance and monitoring systems, which will support long-term market growth. As reflected in its Joint External Evaluation and Global Health Security Index scores, Vietnam's impressive performance in global health security indicators highlights the healthcare system's growing capacity to implement point-of-care diagnostics in the coming years.

The break-up of the profile of primary participants in the ASEAN point of care diagnostics market:

  • By Company Type: Tier 1 - 40%, Tier 2 - 30%, and Tier 3 - 30%
  • By Designation: C-level - 27%, D-level - 18%, and Others - 55%

The key players in this market are Abbott (US), F. Hoffmann-La Roche Ltd. (Switzerland), Siemens Healthineers AG (Germany), Sysmex Corporation (Japan), Danaher Corporation (US), BD (US), QuidelOrtho Corporation (US), Cardinal Health (US), AccuBioTech Co., Ltd. (China), EKF Diagnostics Holdings plc (UK), bioMerieux (France), Thermo Fisher Scientific Inc. (US), BIOSYNEX SA (France), PTS Diagnostics (US), LifeScan IP Holdings, LLC (US), SD Biosensor, INC. (South Korea), CTK Biotech, Inc. (US), Wondfo (China), Trinity Biotech (Ireland), SEKISUI Diagnostics (US), Werfen (Spain), ARKRAY, Inc. (US), Xiamen Boson Biotech Co., Ltd. (China), Credo Diagnostics Biomedical Pte. Ltd. (Singapore), Anbio Biotechnology Inc. (Germany), and SG Diagnostics (Singapore).

Research Coverage:

This research report categorizes the ASEAN point of care diagnostics market by product (infectious disease testing products, glucose monitoring products, cardiometabolic testing products, coagulation monitoring products, pregnancy & fertility testing products, urinalysis testing products, cancer marker testing products, cholesterol testing products, hematology testing products, fecal occult testing products, drugs-of-abuse testing products, and other POC products), by technology [lateral flow assays (immunoassays), rapid tests (molecular diagnostics), and biochemistry], by end user (clinical laboratories, hospitals and critical care centers, outpatient settings and ambulatory care centers, home care settings, and other end users) and by country (Vietnam, Laos, Cambodia, Malaysia, Myanmar, Philippines, Singapore, Thailand, Indonesia, and Brunei). The report provides comprehensive information on the key factors influencing the growth of the ASEAN point-of-care diagnostics market, including drivers, restraints, opportunities, and challenges. It includes a detailed analysis of the major industry players, offering insights into their business overviews, solutions, key strategies, acquisitions, and agreements. Additionally, the report discusses new product and service launches and recent developments in the point-of-care diagnostics market. A competitive analysis of emerging startups within the ASEAN point-of-care diagnostics ecosystem is also included.

Reasons to buy this report:

The report will help market leaders and new entrants with information on the closest approximations of the revenue numbers for the ASEAN point of care diagnostics market and its subsegments. It will also help stakeholders understand the competitive landscape and gain more insights to better position their businesses and plan suitable go-to-market strategies. The report also helps stakeholders understand the market pulse and provides information on key market drivers, restraints, opportunities, and challenges.

The report provides insights into the following points:

  • Analysis of key drivers [Rising incidence of infectious diseases, increasing prevalence of chronic diseases, favorable government initiatives for POC testing, and the rising number of Public-Private Partnerships (PPPs)], opportunities (Gradual shift toward decentralized healthcare systems and availability of POC tests with multiplexing capabilities), restraints (Pricing pressure on manufacturers and stringent regulatory approval process for product commercialization), and challenges (Shortage of skilled healthcare providers and premium pricing of novel platforms) that influence the growth of the ASEAN point of care diagnostics market.
  • Product Development/Innovation: Detailed insights on upcoming technologies, research & development activities, and new product launches in the ASEAN point of care diagnostics market.
  • Market Development: Comprehensive information about lucrative markets-the report analyses the ASEAN point of care diagnostics market across various countries.
  • Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the ASEAN point of care diagnostics market.
  • Competitive Assessment: In-depth assessment of market shares, growth strategies, and product offerings of leading players like Abbott (US), F. Hoffmann-La Roche Ltd. (Switzerland), Siemens Healthineers AG (Germany), Sysmex Corporation (Japan), and Danaher Corporation (US).
Show more
Product Code: MD 8010

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 STUDY OBJECTIVES
  • 1.2 MARKET DEFINITION
  • 1.3 STUDY SCOPE
    • 1.3.1 MARKET SCOPE
    • 1.3.2 INCLUSIONS & EXCLUSIONS
    • 1.3.3 YEARS CONSIDERED
    • 1.3.4 CURRENCY CONSIDERED
  • 1.4 KEY STAKEHOLDERS
  • 1.5 SUMMARY OF CHANGES

2 RESEARCH METHODOLOGY

  • 2.1 RESEARCH DATA
    • 2.1.1 SECONDARY DATA
      • 2.1.1.1 Key secondary sources
      • 2.1.1.2 Key data from secondary sources
      • 2.1.1.3 Key objectives
    • 2.1.2 PRIMARY DATA
      • 2.1.2.1 Key primary sources
      • 2.1.2.2 Key data from primary sources
      • 2.1.2.3 Key industry insights
  • 2.2 MARKET SIZE ESTIMATION
    • 2.2.1 BOTTOM-UP APPROACH
      • 2.2.1.1 Company revenue estimation approach
      • 2.2.1.2 Presentations of companies & primary interviews
      • 2.2.1.3 Growth forecast
      • 2.2.1.4 CAGR projections
    • 2.2.2 TOP-DOWN APPROACH
  • 2.3 DATA TRIANGULATION
  • 2.4 MARKET SHARE ANALYSIS
  • 2.5 RESEARCH ASSUMPTIONS
    • 2.5.1 GROWTH RATE ASSUMPTIONS
  • 2.6 RESEARCH LIMITATIONS
  • 2.7 RISK ASSESSMENT

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS

  • 4.1 ASEAN POINT OF CARE DIAGNOSTICS MARKET OVERVIEW
  • 4.2 ASEAN POINT OF CARE DIAGNOSTICS MARKET, BY PRODUCT, 2025 VS. 2030
  • 4.3 ASEAN POINT OF CARE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2025 VS. 2030
  • 4.4 ASEAN POINT OF CARE DIAGNOSTICS MARKET, BY END USER, 2025 VS. 2030
  • 4.5 ASEAN POINT OF CARE DIAGNOSTICS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES

5 MARKET OVERVIEW

  • 5.1 INTRODUCTION
  • 5.2 MARKET DYNAMICS
    • 5.2.1 DRIVERS
      • 5.2.1.1 Rising incidence of infectious diseases
      • 5.2.1.2 Increasing prevalence of chronic diseases
      • 5.2.1.3 Favorable government initiatives for POC testing
      • 5.2.1.4 Rising number of public-private partnerships (PPPs)
    • 5.2.2 RESTRAINTS
      • 5.2.2.1 Pricing pressure on manufacturers
      • 5.2.2.2 Stringent regulatory approval process for product commercialization
    • 5.2.3 OPPORTUNITIES
      • 5.2.3.1 Gradual shift toward decentralized healthcare systems
      • 5.2.3.2 Availability of POC tests with multiplexing capabilities
    • 5.2.4 CHALLENGES
      • 5.2.4.1 Shortage of skilled healthcare providers
      • 5.2.4.2 Premium pricing of novel platforms
  • 5.3 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS' BUSINESSES
  • 5.4 PRICING ANALYSIS
    • 5.4.1 INDICATIVE SELLING PRICE TREND OF POC TESTS, BY PRODUCT
    • 5.4.2 INDICATIVE SELLING PRICE TREND OF GLUCOSE TEST STRIPS, BY KEY PLAYER
    • 5.4.3 INDICATIVE SELLING PRICE TREND OF POC PREGNANCY TEST KITS, BY COUNTRY
  • 5.5 VALUE CHAIN ANALYSIS
  • 5.6 SUPPLY CHAIN ANALYSIS
  • 5.7 ECOSYSTEM ANALYSIS
  • 5.8 INVESTMENT & FUNDING SCENARIO
  • 5.9 TECHNOLOGY ANALYSIS
    • 5.9.1 KEY TECHNOLOGIES
      • 5.9.1.1 Lateral flow assays
    • 5.9.2 COMPLEMENTARY TECHNOLOGIES
      • 5.9.2.1 Molecular diagnostics
    • 5.9.3 ADJACENT TECHNOLOGIES
      • 5.9.3.1 Biochemical technologies
  • 5.10 PATENT ANALYSIS
  • 5.11 TRADE ANALYSIS
    • 5.11.1 IMPORT DATA FOR HS CODE 3822
    • 5.11.2 EXPORT DATA FOR HS CODE 3822
  • 5.12 KEY CONFERENCES & EVENTS, 2025-2026
  • 5.13 REGULATORY ANALYSIS
    • 5.13.1 REGULATORY LANDSCAPE
      • 5.13.1.1 Vietnam
      • 5.13.1.2 Laos
      • 5.13.1.3 Cambodia
      • 5.13.1.4 Malaysia
      • 5.13.1.5 Myanmar
      • 5.13.1.6 Philippines
      • 5.13.1.7 Singapore
      • 5.13.1.8 Thailand
      • 5.13.1.9 Indonesia
      • 5.13.1.10 Brunei
    • 5.13.2 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • 5.14 PORTER'S FIVE FORCES ANALYSIS
    • 5.14.1 THREAT OF NEW ENTRANTS
    • 5.14.2 THREAT OF SUBSTITUTES
    • 5.14.3 BARGAINING POWER OF BUYERS
    • 5.14.4 BARGAINING POWER OF SUPPLIERS
    • 5.14.5 INTENSITY OF COMPETITIVE RIVALRY
  • 5.15 KEY STAKEHOLDERS & BUYING CRITERIA
    • 5.15.1 KEY STAKEHOLDERS IN BUYING PROCESS
    • 5.15.2 KEY BUYING CRITERIA
  • 5.16 IMPACT OF AI ON ASEAN POINT OF CARE DIAGNOSTICS MARKET
    • 5.16.1 INTRODUCTION
    • 5.16.2 MARKET POTENTIAL OF AI IN POC DIAGNOSTIC APPLICATIONS
    • 5.16.3 AI USE CASES
    • 5.16.4 KEY COMPANIES IMPLEMENTING AI
    • 5.16.5 FUTURE OF AI IN ASEAN POINT OF CARE DIAGNOSTICS MARKET

6 ASEAN POINT OF CARE DIAGNOSTICS MARKET, BY PRODUCT

  • 6.1 INTRODUCTION
  • 6.2 GLUCOSE MONITORING PRODUCTS
    • 6.2.1 GLUCOMETERS
      • 6.2.1.1 Accurate monitoring of blood sugar levels to drive market
    • 6.2.2 GLUCOSE TEST STRIPS
      • 6.2.2.1 Increasing uptake of single-use products to fuel market
    • 6.2.3 LANCETS
      • 6.2.3.1 Increasing preference for home-based care to support market growth
  • 6.3 INFECTIOUS DISEASE TESTING PRODUCTS
    • 6.3.1 RESPIRATORY INFECTION TESTING PRODUCTS
      • 6.3.1.1 TB testing products
        • 6.3.1.1.1 High prevalence of tuberculosis cases to fuel market
      • 6.3.1.2 Influenza testing products
        • 6.3.1.2.1 Rising need for targeted treatment therapies to boost demand
      • 6.3.1.3 Other respiratory infection testing products
    • 6.3.2 MOSQUITO-BORNE DISEASE TESTING PRODUCTS
      • 6.3.2.1 Rising incidence of malaria & dengue to boost demand
    • 6.3.3 STD TESTING PRODUCTS
      • 6.3.3.1 Need to reduce disease transmission rates to facilitate growth
    • 6.3.4 HIV TESTING PRODUCTS
      • 6.3.4.1 Growing awareness of HIV POC testing to boost demand
    • 6.3.5 HAI TESTING PRODUCTS
      • 6.3.5.1 Growing incidence of HAIs in healthcare settings to drive market
    • 6.3.6 HEPATITIS TESTING PRODUCTS
      • 6.3.6.1 Hepatitis B testing products
        • 6.3.6.1.1 Increasing prevalence of liver infections to fuel market
      • 6.3.6.2 Hepatitis C testing products
        • 6.3.6.2.1 Rising need to combat hepatitis among high-risk subgroups to support market growth
    • 6.3.7 OTHER INFECTIOUS DISEASE TESTING PRODUCTS
  • 6.4 COVID-19 TESTING PRODUCTS
    • 6.4.1 GRADUAL SHIFT TOWARDS SYNDROMIC TESTING TO SUPPORT MARKET GROWTH
  • 6.5 CARDIOMETABOLIC TESTING PRODUCTS
    • 6.5.1 CARDIAC MARKER TESTING PRODUCTS
      • 6.5.1.1 Early detection of myocardial infarctions and acute coronary syndromes to fuel market
    • 6.5.2 HBA1C TESTING PRODUCTS
      • 6.5.2.1 Provision of long-term measurement in blood glucose control to boost demand
    • 6.5.3 BLOOD GAS & ELECTROLYTE TESTING PRODUCTS
      • 6.5.3.1 Monitoring of key parameters for pH and oxygen saturation to drive market
  • 6.6 COAGULATION MONITORING PRODUCTS
    • 6.6.1 HIGH INCIDENCE OF BLEEDING DISORDERS TO FUEL UPTAKE
  • 6.7 PREGNANCY & FERTILITY TESTING PRODUCTS
    • 6.7.1 GROWING AWARENESS OF SUSTAINABLE FAMILY PLANNING TO PROPEL MARKET
  • 6.8 HEMATOLOGY TESTING PRODUCTS
    • 6.8.1 RISING DEMAND FOR BLOOD TRANSFUSION PROCEDURES TO DRIVE MARKET
  • 6.9 CANCER MARKER TESTING PRODUCTS
    • 6.9.1 INCREASING PREFERENCE FOR PERSONALIZED ONCOLOGY THERAPEUTICS TO PROPEL MARKET
  • 6.10 FECAL OCCULT TESTING PRODUCTS
    • 6.10.1 FAVORABLE INITIATIVES FOR COLORECTAL CANCER SCREENING TO BOOST MARKET
  • 6.11 CHOLESTEROL TESTING PRODUCTS
    • 6.11.1 RISING OBESITY RATE CAUSED BY SEDENTARY LIFESTYLES TO DRIVE MARKET
  • 6.12 URINALYSIS TESTING PRODUCTS
    • 6.12.1 RISING PREVALENCE OF UTIS AND KIDNEY DISEASES TO DRIVE MARKET
  • 6.13 DRUGS-OF-ABUSE TESTING PRODUCTS
    • 6.13.1 HIGH CONSUMPTION OF ILLICIT DRUGS TO FUEL MARKET
  • 6.14 OTHER POC PRODUCTS

7 ASEAN POINT OF CARE DIAGNOSTICS MARKET, BY TECHNOLOGY

  • 7.1 INTRODUCTION
  • 7.2 BIOCHEMISTRY
    • 7.2.1 PROVISION OF RAPID ONSITE RESULTS FOR CHRONIC CONDITIONS TO DRIVE MARKET
  • 7.3 LATERAL FLOW ASSAYS (IMMUNOASSAYS)
    • 7.3.1 INTEGRATION OF ELISA INTO DISPOSABLE TESTING STRIPS FOR COMPLEX LABORATORY ANALYSIS TO FUEL MARKET
  • 7.4 RAPID TESTS (MOLECULAR DIAGNOSTICS)
    • 7.4.1 ANALYSIS OF BIOLOGICAL MARKERS FOR RAPID DISEASE DETECTION TO PROPEL MARKET

8 ASEAN POINT OF CARE DIAGNOSTICS MARKET, BY END USER

  • 8.1 INTRODUCTION
  • 8.2 HOME CARE SETTINGS
    • 8.2.1 GROWING CONSUMER PREFERENCE FOR CONVENIENCE AND AFFORDABILITY TO PROPEL MARKET
  • 8.3 CLINICAL LABORATORIES
    • 8.3.1 MANAGEMENT OF HIGH PATIENT VOLUMES WITH AUTOMATED TESTING SOLUTIONS TO FUEL MARKET
  • 8.4 HOSPITALS AND CRITICAL CARE CENTERS
    • 8.4.1 RISING REQUIREMENT FOR RAPID POC TESTING IN EMERGENCY USE TO SUPPORT MARKET GROWTH
  • 8.5 OUTPATIENT SETTINGS AND AMBULATORY CARE CENTERS
    • 8.5.1 COST-EFFECTIVENESS OVER HOSPITALS TO BOOST MARKET GROWTH
  • 8.6 OTHER END USERS

9 ASEAN POINT OF CARE DIAGNOSTICS MARKET, BY COUNTRY

  • 9.1 INTRODUCTION
    • 9.1.1 MACROECONOMIC OUTLOOK FOR ASEAN COUNTRIES
  • 9.2 INDONESIA
    • 9.2.1 RISING PUBLIC AWARENESS ABOUT PREVENTIVE HEALTHCARE TO DRIVE MARKET
    • 9.2.2 MACROECONOMIC OUTLOOK FOR INDONESIA
  • 9.3 THAILAND
    • 9.3.1 EXPANDING GERIATRIC POPULATION AND SUBSEQUENT RISE IN CHRONIC DISEASES TO FUEL MARKET
    • 9.3.2 MACROECONOMIC OUTLOOK FOR THAILAND
  • 9.4 MALAYSIA
    • 9.4.1 HIGH INCIDENCE OF DIABETES TO BOOST DEMAND
    • 9.4.2 MACROECONOMIC OUTLOOK FOR MALAYSIA
  • 9.5 PHILIPPINES
    • 9.5.1 IMPROVED HEALTHCARE ACCESS AND INSURANCE COVERAGE TO FUEL ADOPTION
    • 9.5.2 MACROECONOMIC OUTLOOK FOR PHILIPPINES
  • 9.6 VIETNAM
    • 9.6.1 IMPROVING HEALTHCARE INFRASTRUCTURE AND FAVORABLE GOVERNMENT INITIATIVES TO PROPEL MARKET
    • 9.6.2 MACROECONOMIC OUTLOOK FOR VIETNAM
  • 9.7 SINGAPORE
    • 9.7.1 INCREASING DEMAND FOR SPECIALIZED MEDICAL SERVICES TO BOOST MARKET
    • 9.7.2 MACROECONOMIC OUTLOOK FOR SINGAPORE
  • 9.8 MYANMAR
    • 9.8.1 RISING NEED FOR AFFORDABLE DIAGNOSTIC SOLUTIONS TO DRIVE MARKET
    • 9.8.2 MACROECONOMIC OUTLOOK FOR MYANMAR
  • 9.9 CAMBODIA
    • 9.9.1 RISING PREVALENCE OF NCDS TO SUPPORT MARKET GROWTH
    • 9.9.2 MACROECONOMIC OUTLOOK FOR CAMBODIA
  • 9.10 LAOS
    • 9.10.1 NEED FOR DECENTRALIZED DIAGNOSTIC SOLUTIONS TO FUEL DEMAND
    • 9.10.2 MACROECONOMIC OUTLOOK FOR LAOS
  • 9.11 BRUNEI
    • 9.11.1 GROWING NEED FOR COST-EFFECTIVE POC SOLUTIONS TO FUEL MARKET
    • 9.11.2 MACROECONOMIC OUTLOOK FOR BRUNEI

10 COMPETITIVE LANDSCAPE

  • 10.1 INTRODUCTION
  • 10.2 KEY PLAYER STRATEGIES/RIGHT TO WIN
    • 10.2.1 OVERVIEW OF STRATEGIES ADOPTED BY PLAYERS IN ASEAN POINT OF CARE DIAGNOSTICS MARKET
  • 10.3 REVENUE ANALYSIS, 2022-2024
  • 10.4 MARKET SHARE ANALYSIS, 2024
  • 10.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2024
    • 10.5.1 STARS
    • 10.5.2 EMERGING LEADERS
    • 10.5.3 PERVASIVE PLAYERS
    • 10.5.4 PARTICIPANTS
    • 10.5.5 COMPANY FOOTPRINT, KEY PLAYERS, 2024
      • 10.5.5.1 Company footprint
      • 10.5.5.2 Country footprint
      • 10.5.5.3 Product footprint
      • 10.5.5.4 Technology footprint
  • 10.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2024
    • 10.6.1 PROGRESSIVE COMPANIES
    • 10.6.2 RESPONSIVE COMPANIES
    • 10.6.3 DYNAMIC COMPANIES
    • 10.6.4 STARTING BLOCKS
    • 10.6.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2024
      • 10.6.5.1 Detailed list of key startups/SMEs
      • 10.6.5.2 Competitive benchmarking of key startups/SMEs, by technology
      • 10.6.5.3 Competitive benchmarking of key startups/SMEs, by country
  • 10.7 COMPANY VALUATION & FINANCIAL METRICS
    • 10.7.1 FINANCIAL METRICS
    • 10.7.2 COMPANY VALUATION
  • 10.8 BRAND/PRODUCT COMPARISON
  • 10.9 COMPETITIVE SCENARIO
    • 10.9.1 PRODUCT LAUNCHES & APPROVALS
    • 10.9.2 DEALS
    • 10.9.3 EXPANSIONS

11 COMPANY PROFILES

  • 11.1 KEY PLAYERS
    • 11.1.1 ABBOTT
      • 11.1.1.1 Business overview
      • 11.1.1.2 Products offered
      • 11.1.1.3 Recent developments
        • 11.1.1.3.1 Product approvals
        • 11.1.1.3.2 Deals
      • 11.1.1.4 MnM view
        • 11.1.1.4.1 Key strengths
        • 11.1.1.4.2 Strategic choices
        • 11.1.1.4.3 Weaknesses & competitive threats
    • 11.1.2 F. HOFFMANN-LA ROCHE LTD.
      • 11.1.2.1 Business overview
      • 11.1.2.2 Products offered
      • 11.1.2.3 Recent developments
        • 11.1.2.3.1 Product launches & approvals
        • 11.1.2.3.2 Deals
      • 11.1.2.4 MnM view
        • 11.1.2.4.1 Key strengths
        • 11.1.2.4.2 Strategic choices
        • 11.1.2.4.3 Weaknesses & competitive threats
    • 11.1.3 SIEMENS HEALTHINEERS AG
      • 11.1.3.1 Business overview
      • 11.1.3.2 Products offered
      • 11.1.3.3 Recent developments
        • 11.1.3.3.1 Product approvals
        • 11.1.3.3.2 Deals
        • 11.1.3.3.3 Expansions
      • 11.1.3.4 MnM view
        • 11.1.3.4.1 Key strengths
        • 11.1.3.4.2 Strategic choices
        • 11.1.3.4.3 Weaknesses & competitive threats
    • 11.1.4 SYSMEX CORPORATION
      • 11.1.4.1 Business overview
      • 11.1.4.2 Products offered
      • 11.1.4.3 Recent developments
        • 11.1.4.3.1 Expansions
      • 11.1.4.4 MnM view
        • 11.1.4.4.1 Key strengths
        • 11.1.4.4.2 Strategic choices
        • 11.1.4.4.3 Weaknesses & competitive threats
    • 11.1.5 DANAHER CORPORATION
      • 11.1.5.1 Business overview
      • 11.1.5.2 Products offered
      • 11.1.5.3 MnM view
        • 11.1.5.3.1 Key strengths
        • 11.1.5.3.2 Strategic choices
        • 11.1.5.3.3 Weaknesses and competitive threats
    • 11.1.6 BD
      • 11.1.6.1 Business overview
      • 11.1.6.2 Products offered
      • 11.1.6.3 Recent developments
        • 11.1.6.3.1 Deals
        • 11.1.6.3.2 Expansions
    • 11.1.7 QUIDELORTHO CORPORATION
      • 11.1.7.1 Business overview
      • 11.1.7.2 Recent developments
        • 11.1.7.2.1 Product approvals
        • 11.1.7.2.2 Deals
        • 11.1.7.2.3 Expansions
    • 11.1.8 CARDINAL HEALTH
      • 11.1.8.1 Business overview
      • 11.1.8.2 Products offered
      • 11.1.8.3 Recent developments
        • 11.1.8.3.1 Deals
        • 11.1.8.3.2 Expansions
    • 11.1.9 BIOMERIEUX
      • 11.1.9.1 Business overview
      • 11.1.9.2 Products offered
      • 11.1.9.3 Recent developments
        • 11.1.9.3.1 Product approvals
        • 11.1.9.3.2 Deals
    • 11.1.10 EKF DIAGNOSTICS HOLDINGS PLC
      • 11.1.10.1 Business overview
      • 11.1.10.2 Products offered
      • 11.1.10.3 Recent developments
        • 11.1.10.3.1 Product launches
        • 11.1.10.3.2 Deals
        • 11.1.10.3.3 Expansions
    • 11.1.11 THERMO FISHER SCIENTIFIC INC.
      • 11.1.11.1 Business overview
      • 11.1.11.2 Products offered
      • 11.1.11.3 Recent developments
        • 11.1.11.3.1 Product launches
        • 11.1.11.3.2 Deals
    • 11.1.12 ACCUBIOTECH, CO., LTD.
      • 11.1.12.1 Business overview
      • 11.1.12.2 Products offered
      • 11.1.12.3 Recent developments
        • 11.1.12.3.1 Product approvals
  • 11.2 OTHER PLAYERS
    • 11.2.1 BIOSYNEX SA
    • 11.2.2 SD BIOSENSOR, INC.
    • 11.2.3 SEKISUI DIAGNOSTICS
    • 11.2.4 WERFEN
    • 11.2.5 TRINITY BIOTECH
    • 11.2.6 PTS DIAGNOSTICS
    • 11.2.7 LIFESCAN IP HOLDINGS, LLC
    • 11.2.8 CTK BIOTECH, INC.
    • 11.2.9 WONDFO
    • 11.2.10 ARKRAY, INC.
    • 11.2.11 XIAMEN BOSON BIOTECH CO., LTD.
    • 11.2.12 CREDO DIAGNOSTICS BIOMEDICAL PTE. LTD.
    • 11.2.13 ANBIO BIOTECHNOLOGY INC.
    • 11.2.14 SG DIAGNOSTICS

12 APPENDIX

  • 12.1 DISCUSSION GUIDE
  • 12.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
  • 12.3 AVAILABLE CUSTOMIZATIONS
  • 12.4 RELATED REPORTS
  • 12.5 AUTHOR DETAILS
Show more
Product Code: MD 8010

List of Tables

  • TABLE 1 ASEAN POINT OF CARE DIAGNOSTICS MARKET: KEY DATA FROM PRIMARY SOURCES
  • TABLE 2 ASEAN POINT OF CARE DIAGNOSTICS MARKET: RISK ASSESSMENT ANALYSIS
  • TABLE 3 HEPATITIS DISEASE BURDEN AND DEATHS CAUSED BY HEPATITIS, BY COUNTRY (2022)
  • TABLE 4 DIABETES ESTIMATES (AGES 20-79) AND DIABETES-RELATED DEATHS, BY COUNTRY, 2021
  • TABLE 5 PROJECTED INCREASE IN CANCER PATIENTS, BY COUNTRY, 2022 VS. 2035 VS. 2045
  • TABLE 6 INDICATIVE SELLING PRICE TREND OF POC TESTS, BY PRODUCT, 2023-2025
  • TABLE 7 INDICATIVE SELLING PRICE TREND OF GLUCOSE TEST STRIPS, BY KEY PLAYER, 2023-2025
  • TABLE 8 INDICATIVE SELLING PRICE TREND OF POC PREGNANCY TEST KITS, BY COUNTRY, 2023-2025
  • TABLE 9 ASEAN POINT OF CARE DIAGNOSTICS MARKET: ROLE IN ECOSYSTEM
  • TABLE 10 ASEAN POINT OF CARE DIAGNOSTICS MARKET: INNOVATIONS & PATENT REGISTRATIONS, 2022-2024
  • TABLE 11 IMPORT DATA FOR DIAGNOSTIC & LABORATORY REAGENTS (HS CODE 3822), BY COUNTRY, 2020-2024 (USD THOUSAND)
  • TABLE 12 EXPORT DATA FOR DIAGNOSTIC & LABORATORY REAGENTS (HS CODE 3822), BY COUNTRY, 2020-2024 (USD THOUSAND)
  • TABLE 13 ASEAN POC DIAGNOSTICS MARKET: KEY CONFERENCES & EVENTS, 2025-2026
  • TABLE 14 MALAYSIA: CLASSIFICATION OF IVD MEDICAL DEVICES
  • TABLE 15 MYANMAR: CLASSIFICATION OF IVD MEDICAL DEVICES
  • TABLE 16 ASEAN COUNTRIES: KEY REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 17 ASEAN POINT OF CARE DIAGNOSTICS MARKET: PORTER'S FIVE FORCES ANALYSIS
  • TABLE 18 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS, BY TECHNOLOGY (%)
  • TABLE 19 KEY BUYING CRITERIA, BY TECHNOLOGY
  • TABLE 20 ASEAN POINT OF CARE DIAGNOSTICS MARKET, BY PRODUCT, 2022-2030 (USD MILLION)
  • TABLE 21 DIABETES PREVALENCE (20-79 YRS), DIABETES-RELATED DEATHS, AND PROPORTION OF UNDIAGNOSED DIABETES, BY COUNTRY, 2021
  • TABLE 22 ASEAN POINT OF CARE DIAGNOSTICS MARKET FOR GLUCOSE MONITORING PRODUCTS, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 23 ASEAN POINT OF CARE DIAGNOSTICS MARKET FOR GLUCOSE MONITORING PRODUCTS, BY COUNTRY, 2022-2030 (USD MILLION)
  • TABLE 24 GLUCOMETERS: CURRENTLY AVAILABLE PRODUCTS, BY COMPANY
  • TABLE 25 ASEAN POINT OF CARE DIAGNOSTICS MARKET FOR GLUCOMETERS, BY COUNTRY, 2022-2030 (USD MILLION)
  • TABLE 26 GLUCOSE TEST STRIPS: CURRENTLY AVAILABLE PRODUCTS, BY COMPANY
  • TABLE 27 ASEAN POINT OF CARE DIAGNOSTICS MARKET FOR GLUCOSE TEST STRIPS, BY COUNTRY, 2022-2030 (USD MILLION)
  • TABLE 28 LANCETS & LANCING DEVICES: CURRENTLY AVAILABLE PRODUCTS, BY COMPANY
  • TABLE 29 ASEAN POINT OF CARE DIAGNOSTICS MARKET FOR LANCETS, BY COUNTRY, 2022-2030 (USD MILLION)
  • TABLE 30 ASEAN POINT OF CARE DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE TESTING PRODUCTS, BY DISEASE TYPE, 2022-2030 (USD MILLION)
  • TABLE 31 ASEAN POINT OF CARE DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE TESTING PRODUCTS, BY COUNTRY, 2022-2030 (USD MILLION)
  • TABLE 32 ASEAN POINT OF CARE DIAGNOSTICS MARKET FOR RESPIRATORY INFECTION TESTING PRODUCTS, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 33 ASEAN POINT OF CARE DIAGNOSTICS MARKET FOR RESPIRATORY INFECTION TESTING PRODUCTS, BY COUNTRY, 2022-2030 (USD MILLION)
  • TABLE 34 TB TESTING: CURRENTLY AVAILABLE PRODUCTS, BY COMPANY
  • TABLE 35 ASEAN POINT OF CARE DIAGNOSTICS MARKET FOR TB TESTING PRODUCTS, BY COUNTRY, 2022-2030 (USD MILLION)
  • TABLE 36 INFLUENZA TESTING: CURRENTLY AVAILABLE PRODUCTS, BY COMPANY
  • TABLE 37 ASEAN POINT OF CARE DIAGNOSTICS MARKET FOR INFLUENZA TESTING PRODUCTS, BY COUNTRY, 2022-2030 (USD MILLION)
  • TABLE 38 OTHER RESPIRATORY INFECTION TESTING: CURRENTLY AVAILABLE PRODUCTS, BY COMPANY
  • TABLE 39 ASEAN POINT OF CARE DIAGNOSTICS MARKET FOR OTHER RESPIRATORY INFECTION TESTING PRODUCTS, BY COUNTRY, 2022-2030 (USD MILLION)
  • TABLE 40 MOSQUITO-BORNE DISEASE TESTING: CURRENTLY AVAILABLE PRODUCTS, BY COMPANY
  • TABLE 41 ASEAN POINT OF CARE DIAGNOSTICS MARKET FOR MOSQUITO-BORNE DISEASE TESTING PRODUCTS, BY COUNTRY, 2022-2030 (USD MILLION)
  • TABLE 42 STD TESTING: CURRENTLY AVAILABLE PRODUCTS, BY COMPANY
  • TABLE 43 ASEAN POINT OF CARE DIAGNOSTICS MARKET FOR STD TESTING PRODUCTS, BY COUNTRY, 2022-2030 (USD MILLION)
  • TABLE 44 HIV TESTING: CURRENTLY AVAILABLE PRODUCTS, BY COMPANY
  • TABLE 45 ASEAN POINT OF CARE DIAGNOSTICS MARKET FOR HIV TESTING PRODUCTS, BY COUNTRY, 2022-2030 (USD MILLION)
  • TABLE 46 HAI TESTING: CURRENTLY AVAILABLE PRODUCTS, BY COMPANY
  • TABLE 47 ASEAN POINT OF CARE DIAGNOSTICS MARKET FOR HAI TESTING PRODUCTS, BY COUNTRY, 2022-2030 (USD MILLION)
  • TABLE 48 ASEAN POINT OF CARE DIAGNOSTICS MARKET FOR HEPATITIS TESTING PRODUCTS, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 49 ASEAN POINT OF CARE DIAGNOSTICS MARKET FOR HEPATITIS TESTING PRODUCTS, BY COUNTRY, 2022-2030 (USD MILLION)
  • TABLE 50 HEPATITIS B TESTING: CURRENTLY AVAILABLE PRODUCTS, BY COMPANY
  • TABLE 51 ASEAN POINT OF CARE DIAGNOSTICS MARKET FOR HEPATITIS B TESTING PRODUCTS, BY COUNTRY, 2022-2030 (USD MILLION)
  • TABLE 52 HEPATITIS C TESTING: CURRENTLY AVAILABLE PRODUCTS, BY COMPANY
  • TABLE 53 ASEAN POINT OF CARE DIAGNOSTICS MARKET FOR HEPATITIS C TESTING PRODUCTS, BY COUNTRY, 2022-2030 (USD MILLION)
  • TABLE 54 OTHER INFECTIOUS DISEASE TESTING: CURRENTLY AVAILABLE PRODUCTS, BY COMPANY
  • TABLE 55 ASEAN POINT OF CARE DIAGNOSTICS MARKET FOR OTHER INFECTIOUS DISEASE TESTING PRODUCTS, BY COUNTRY, 2022-2030 (USD MILLION)
  • TABLE 56 ASEAN POINT OF CARE DIAGNOSTICS MARKET FOR COVID-19 TESTING PRODUCTS, BY COUNTRY, 2022-2030 (USD MILLION)
  • TABLE 57 CARDIOMETABOLIC TESTING: CURRENTLY AVAILABLE PRODUCTS, BY COMPANY
  • TABLE 58 ASEAN POINT OF CARE DIAGNOSTICS MARKET FOR CARDIOMETABOLIC TESTING PRODUCTS, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 59 ASEAN POINT OF CARE DIAGNOSTICS MARKET FOR CARDIOMETABOLIC TESTING PRODUCTS, BY COUNTRY, 2022-2030 (USD MILLION)
  • TABLE 60 ASEAN POINT OF CARE DIAGNOSTICS MARKET FOR CARDIAC MARKER TESTING PRODUCTS, BY COUNTRY, 2022-2030 (USD MILLION)
  • TABLE 61 ASEAN POINT OF CARE DIAGNOSTICS MARKET FOR HBA1C TESTING PRODUCTS, BY COUNTRY, 2022-2030 (USD MILLION)
  • TABLE 62 ASEAN POINT OF CARE DIAGNOSTICS MARKET FOR BLOOD GAS & ELECTROLYTE TESTING PRODUCTS, BY COUNTRY, 2022-2030 (USD MILLION)
  • TABLE 63 COAGULATION MONITORING: CURRENTLY AVAILABLE PRODUCTS, BY COMPANY
  • TABLE 64 ASEAN POINT OF CARE DIAGNOSTICS MARKET FOR COAGULATION MONITORING PRODUCTS, BY COUNTRY, 2022-2030 (USD MILLION)
  • TABLE 65 PREGNANCY & FERTILITY TESTING: CURRENTLY AVAILABLE PRODUCTS, BY COMPANY
  • TABLE 66 ASEAN POINT OF CARE DIAGNOSTICS MARKET FOR PREGNANCY & FERTILITY TESTING PRODUCTS, BY COUNTRY, 2022-2030 (USD MILLION)
  • TABLE 67 ASEAN POINT OF CARE DIAGNOSTICS MARKET: TOTAL NUMBER OF PREGNANCIES, BY COUNTRY, 2022-2030 (IN MILLION)
  • TABLE 68 HEMATOLOGY TESTING: CURRENTLY AVAILABLE PRODUCTS, BY COMPANY
  • TABLE 69 ASEAN POINT OF CARE DIAGNOSTICS MARKET FOR HEMATOLOGY TESTING PRODUCTS, BY COUNTRY, 2022-2030 (USD MILLION)
  • TABLE 70 NUMBER OF CASES FOR TOP FIVE CANCER TYPES, 2022
  • TABLE 71 CANCER MARKER TESTING: CURRENTLY AVAILABLE PRODUCTS, BY COMPANY
  • TABLE 72 ASEAN POINT OF CARE DIAGNOSTICS MARKET OF CANCER MARKER TESTING PRODUCTS, BY COUNTRY, 2022-2030 (USD MILLION)
  • TABLE 73 ESTIMATED NUMBER OF NEW CASES OF COLORECTAL CANCER, 2022 VS. 2035 VS. 2045
  • TABLE 74 FECAL OCCULT BLOOD TESTING: CURRENTLY AVAILABLE PRODUCTS, BY COMPANY
  • TABLE 75 ASEAN POINT OF CARE DIAGNOSTICS MARKET FOR FECAL OCCULT BLOOD TESTING PRODUCTS, BY COUNTRY, 2022-2030 (USD MILLION)
  • TABLE 76 CHOLESTEROL TESTING PRODUCTS: CURRENTLY AVAILABLE PRODUCTS, BY COMPANY
  • TABLE 77 ASEAN POINT OF CARE DIAGNOSTICS MARKET FOR CHOLESTEROL TESTING PRODUCTS, BY COUNTRY, 2022-2030 (USD MILLION)
  • TABLE 78 URINALYSIS TESTING: CURRENTLY AVAILABLE PRODUCTS, BY COMPANY
  • TABLE 79 ASEAN POINT OF CARE DIAGNOSTICS MARKET FOR URINALYSIS TESTING PRODUCTS, BY COUNTRY, 2022-2030 (USD MILLION)
  • TABLE 80 DRUGS-OF-ABUSE TESTING: CURRENTLY AVAILABLE PRODUCTS, BY COMPANY
  • TABLE 81 ASEAN POINT OF CARE DIAGNOSTICS MARKET FOR DRUGS-OF-ABUSE TESTING PRODUCTS, BY COUNTRY, 2022-2030 (USD MILLION)
  • TABLE 82 OTHER POC PRODUCTS: CURRENTLY AVAILABLE PRODUCTS, BY COMPANY
  • TABLE 83 ASEAN POINT OF CARE DIAGNOSTICS MARKET FOR OTHER POC PRODUCTS, BY COUNTRY, 2022-2030 (USD MILLION)
  • TABLE 84 ASEAN POINT OF CARE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022-2030 (USD MILLION)
  • TABLE 85 BIOCHEMISTRY: CURRENTLY AVAILABLE PRODUCTS, BY COMPANY
  • TABLE 86 ASEAN POINT OF CARE DIAGNOSTICS MARKET FOR BIOCHEMISTRY, BY COUNTRY, 2022-2030 (USD MILLION)
  • TABLE 87 LATERAL FLOW ASSAYS: CURRENTLY AVAILABLE PRODUCTS, BY COMPANY
  • TABLE 88 ASEAN POINT OF CARE DIAGNOSTICS MARKET FOR LATERAL FLOW ASSAYS (IMMUNOASSAYS), BY COUNTRY, 2022-2030 (USD MILLION)
  • TABLE 89 ASEAN POINT OF CARE DIAGNOSTICS MARKET FOR RAPID TESTS (MOLECULAR DIAGNOSTICS), BY COUNTRY, 2022-2030 (USD MILLION)
  • TABLE 90 ASEAN POINT OF CARE DIAGNOSTICS MARKET, BY END USER, 2022-2030 (USD MILLION)
  • TABLE 91 ASEAN POINT OF CARE DIAGNOSTICS MARKET FOR HOME CARE SETTINGS, BY COUNTRY, 2022-2030 (USD MILLION)
  • TABLE 92 ASEAN POINT OF CARE DIAGNOSTICS MARKET FOR CLINICAL LABORATORIES, BY COUNTRY, 2022-2030 (USD MILLION)
  • TABLE 93 ASEAN POINT OF CARE DIAGNOSTICS MARKET FOR HOSPITALS AND CRITICAL CARE CENTERS, BY COUNTRY, 2022-2030 (USD MILLION)
  • TABLE 94 ASEAN POINT OF CARE DIAGNOSTICS MARKET FOR OUTPATIENT SETTINGS AND AMBULATORY CARE CENTERS, BY COUNTRY, 2022-2030 (USD MILLION)
  • TABLE 95 ASEAN POINT OF CARE DIAGNOSTICS MARKET FOR OTHER END USERS, BY COUNTRY, 2022-2030 (USD MILLION)
  • TABLE 96 ASEAN POINT OF CARE DIAGNOSTICS MARKET, BY COUNTRY, 2022-2030 (USD MILLION)
  • TABLE 97 INDONESIA: MACROECONOMIC INDICATORS FOR ASEAN POINT OF CARE DIAGNOSTICS MARKET
  • TABLE 98 INDONESIA: ASEAN POINT OF CARE DIAGNOSTICS MARKET, BY PRODUCT, 2022-2030 (USD MILLION)
  • TABLE 99 INDONESIA: ASEAN POINT OF CARE DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE TESTING PRODUCTS, BY DISEASE TYPE, 2022-2030 (USD MILLION)
  • TABLE 100 INDONESIA: ASEAN POINT OF CARE DIAGNOSTICS MARKET FOR RESPIRATORY INFECTION TESTING PRODUCTS, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 101 INDONESIA: ASEAN POINT OF CARE DIAGNOSTICS MARKET FOR HEPATITIS TESTING PRODUCTS, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 102 INDONESIA: ASEAN POINT OF CARE DIAGNOSTICS MARKET FOR GLUCOSE MONITORING PRODUCTS, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 103 INDONESIA: ASEAN POINT OF CARE DIAGNOSTICS MARKET FOR CARDIOMETABOLIC MONITORING PRODUCTS, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 104 INDONESIA: ASEAN POINT OF CARE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022-2030 (USD MILLION)
  • TABLE 105 INDONESIA: ASEAN POINT OF CARE DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE TESTING PRODUCTS, BY TECHNOLOGY, 2022-2030 (USD MILLION)
  • TABLE 106 INDONESIA: ASEAN POINT OF CARE DIAGNOSTICS MARKET, BY END USER, 2022-2030 (USD MILLION)
  • TABLE 107 THAILAND: MACROECONOMIC INDICATORS FOR ASEAN POINT OF CARE DIAGNOSTICS MARKET
  • TABLE 108 THAILAND: ASEAN POINT OF CARE DIAGNOSTICS MARKET, BY PRODUCT, 2022-2030 (USD MILLION)
  • TABLE 109 THAILAND: ASEAN POINT OF CARE DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE TESTING PRODUCTS, BY DISEASE TYPE, 2022-2030 (USD MILLION)
  • TABLE 110 THAILAND: ASEAN POINT OF CARE DIAGNOSTICS MARKET FOR RESPIRATORY INFECTION TESTING PRODUCTS, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 111 THAILAND: ASEAN POINT OF CARE DIAGNOSTICS MARKET FOR HEPATITIS TESTING PRODUCTS, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 112 THAILAND: ASEAN POINT OF CARE DIAGNOSTICS MARKET FOR GLUCOSE MONITORING PRODUCTS, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 113 THAILAND: ASEAN POINT OF CARE DIAGNOSTICS MARKET FOR CARDIOMETABOLIC MONITORING PRODUCTS, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 114 THAILAND: ASEAN POINT OF CARE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022-2030 (USD MILLION)
  • TABLE 115 THAILAND: ASEAN POINT OF CARE DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE TESTING PRODUCTS, BY TECHNOLOGY, 2022-2030 (USD MILLION)
  • TABLE 116 THAILAND: ASEAN POINT OF CARE DIAGNOSTICS MARKET, BY END USER, 2022-2030 (USD MILLION)
  • TABLE 117 MALAYSIA: MACROECONOMIC INDICATORS FOR ASEAN POINT OF CARE DIAGNOSTICS MARKET
  • TABLE 118 MALAYSIA: ASEAN POINT OF CARE DIAGNOSTICS MARKET, BY PRODUCT, 2022-2030 (USD MILLION)
  • TABLE 119 MALAYSIA: ASEAN POINT OF CARE DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE TESTING PRODUCTS, BY DISEASE TYPE, 2022-2030 (USD MILLION)
  • TABLE 120 MALAYSIA: ASEAN POINT OF CARE DIAGNOSTICS MARKET FOR RESPIRATORY INFECTION TESTING PRODUCTS, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 121 MALAYSIA: ASEAN POINT OF CARE DIAGNOSTICS MARKET FOR HEPATITIS TESTING PRODUCTS, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 122 MALAYSIA: ASEAN POINT OF CARE DIAGNOSTICS MARKET FOR GLUCOSE MONITORING PRODUCTS, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 123 MALAYSIA: ASEAN POINT OF CARE DIAGNOSTICS MARKET FOR CARDIOMETABOLIC MONITORING PRODUCTS, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 124 MALAYSIA: ASEAN POINT OF CARE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022-2030 (USD MILLION)
  • TABLE 125 MALAYSIA: ASEAN POINT OF CARE DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE TESTING PRODUCTS, BY TECHNOLOGY, 2022-2030 (USD MILLION)
  • TABLE 126 MALAYSIA: ASEAN POINT OF CARE DIAGNOSTICS MARKET, BY END USER, 2022-2030 (USD MILLION)
  • TABLE 127 PHILIPPINES: MACROECONOMIC INDICATORS FOR ASEAN POINT OF CARE DIAGNOSTICS MARKET
  • TABLE 128 PHILIPPINES: ASEAN POINT OF CARE DIAGNOSTICS MARKET, BY PRODUCT, 2022-2030 (USD MILLION)
  • TABLE 129 PHILIPPINES: ASEAN POINT OF CARE DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE TESTING PRODUCTS, BY DISEASE TYPE, 2022-2030 (USD MILLION)
  • TABLE 130 PHILIPPINES: ASEAN POINT OF CARE DIAGNOSTICS MARKET FOR RESPIRATORY INFECTION TESTING PRODUCTS, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 131 PHILIPPINES: ASEAN POINT OF CARE DIAGNOSTICS MARKET FOR HEPATITIS TESTING PRODUCTS, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 132 PHILIPPINES: ASEAN POINT OF CARE DIAGNOSTICS MARKET FOR GLUCOSE MONITORING PRODUCTS, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 133 PHILIPPINES: ASEAN POINT OF CARE DIAGNOSTICS MARKET FOR CARDIOMETABOLIC MONITORING PRODUCTS, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 134 PHILIPPINES: ASEAN POINT OF CARE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022-2030 (USD MILLION)
  • TABLE 135 PHILIPPINES: ASEAN POINT OF CARE DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE TESTING PRODUCTS, BY TECHNOLOGY, 2022-2030 (USD MILLION)
  • TABLE 136 PHILIPPINES: ASEAN POINT OF CARE DIAGNOSTICS MARKET, BY END USER, 2022-2030 (USD MILLION)
  • TABLE 137 VIETNAM: MACROECONOMIC INDICATORS FOR ASEAN POINT OF CARE DIAGNOSTICS MARKET
  • TABLE 138 VIETNAM: ASEAN POINT OF CARE DIAGNOSTICS MARKET, BY PRODUCT, 2022-2030 (USD MILLION)
  • TABLE 139 VIETNAM: ASEAN POINT OF CARE DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE TESTING PRODUCTS, BY DISEASE TYPE, 2022-2030 (USD MILLION)
  • TABLE 140 VIETNAM: ASEAN POINT OF CARE DIAGNOSTICS MARKET FOR RESPIRATORY INFECTION TESTING PRODUCTS, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 141 VIETNAM: ASEAN POINT OF CARE DIAGNOSTICS MARKET FOR HEPATITIS TESTING PRODUCTS, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 142 VIETNAM: ASEAN POINT OF CARE DIAGNOSTICS MARKET FOR GLUCOSE MONITORING PRODUCTS, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 143 VIETNAM: ASEAN POINT OF CARE DIAGNOSTICS MARKET FOR CARDIOMETABOLIC MONITORING PRODUCTS, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 144 VIETNAM: ASEAN POINT OF CARE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022-2030 (USD MILLION)
  • TABLE 145 VIETNAM: ASEAN POINT OF CARE DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE TESTING PRODUCTS, BY TECHNOLOGY, 2022-2030 (USD MILLION)
  • TABLE 146 VIETNAM: ASEAN POINT OF CARE DIAGNOSTICS MARKET, BY END USER, 2022-2030 (USD MILLION)
  • TABLE 147 SINGAPORE: MACROECONOMIC INDICATORS FOR ASEAN POINT OF CARE DIAGNOSTICS MARKET
  • TABLE 148 SINGAPORE: ASEAN POINT OF CARE DIAGNOSTICS MARKET, BY PRODUCT, 2022-2030 (USD MILLION)
  • TABLE 149 SINGAPORE: ASEAN POINT OF CARE DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE TESTING PRODUCTS, BY DISEASE TYPE, 2022-2030 (USD MILLION)
  • TABLE 150 SINGAPORE: ASEAN POINT OF CARE DIAGNOSTICS MARKET FOR RESPIRATORY INFECTION TESTING PRODUCTS, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 151 SINGAPORE: ASEAN POINT OF CARE DIAGNOSTICS MARKET FOR HEPATITIS TESTING PRODUCTS, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 152 SINGAPORE: ASEAN POINT OF CARE DIAGNOSTICS MARKET FOR GLUCOSE MONITORING PRODUCTS, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 153 SINGAPORE: ASEAN POINT OF CARE DIAGNOSTICS MARKET FOR CARDIOMETABOLIC MONITORING PRODUCTS, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 154 SINGAPORE: ASEAN POINT OF CARE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022-2030 (USD MILLION)
  • TABLE 155 SINGAPORE: ASEAN POINT OF CARE DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE TESTING PRODUCTS, BY TECHNOLOGY, 2022-2030 (USD MILLION)
  • TABLE 156 SINGAPORE: ASEAN POINT OF CARE DIAGNOSTICS MARKET, BY END USER, 2022-2030 (USD MILLION)
  • TABLE 157 MYANMAR: MACROECONOMIC INDICATORS FOR ASEAN POINT OF CARE DIAGNOSTICS MARKET
  • TABLE 158 MYANMAR: ASEAN POINT OF CARE DIAGNOSTICS MARKET, BY PRODUCT, 2022-2030 (USD MILLION)
  • TABLE 159 MYANMAR: ASEAN POINT OF CARE DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE TESTING PRODUCTS, BY DISEASE TYPE, 2022-2030 (USD MILLION)
  • TABLE 160 MYANMAR: ASEAN POINT OF CARE DIAGNOSTICS MARKET FOR RESPIRATORY INFECTION TESTING PRODUCTS, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 161 MYANMAR: ASEAN POINT OF CARE DIAGNOSTICS MARKET FOR HEPATITIS TESTING PRODUCTS, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 162 MYANMAR: ASEAN POINT OF CARE DIAGNOSTICS MARKET FOR GLUCOSE MONITORING PRODUCTS, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 163 MYANMAR: ASEAN POINT OF CARE DIAGNOSTICS MARKET FOR CARDIOMETABOLIC MONITORING PRODUCTS, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 164 MYANMAR: ASEAN POINT OF CARE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022-2030 (USD MILLION)
  • TABLE 165 MYANMAR: ASEAN POINT OF CARE DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE TESTING PRODUCTS, BY TECHNOLOGY, 2022-2030 (USD MILLION)
  • TABLE 166 MYANMAR: ASEAN POINT OF CARE DIAGNOSTICS MARKET, BY END USER, 2022-2030 (USD MILLION)
  • TABLE 167 CAMBODIA: MACROECONOMIC INDICATORS FOR ASEAN POINT OF CARE DIAGNOSTICS MARKET
  • TABLE 168 CAMBODIA: ASEAN POINT OF CARE DIAGNOSTICS MARKET, BY PRODUCT, 2022-2030 (USD MILLION)
  • TABLE 169 CAMBODIA: ASEAN POINT OF CARE DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE TESTING PRODUCTS, BY DISEASE TYPE, 2022-2030 (USD MILLION)
  • TABLE 170 CAMBODIA: ASEAN POINT OF CARE DIAGNOSTICS MARKET FOR RESPIRATORY INFECTION TESTING PRODUCTS, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 171 CAMBODIA: ASEAN POINT OF CARE DIAGNOSTICS MARKET FOR HEPATITIS TESTING PRODUCTS, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 172 CAMBODIA: ASEAN POINT OF CARE DIAGNOSTICS MARKET FOR GLUCOSE MONITORING PRODUCTS, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 173 CAMBODIA: ASEAN POINT OF CARE DIAGNOSTICS MARKET FOR CARDIOMETABOLIC MONITORING PRODUCTS, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 174 CAMBODIA: ASEAN POINT OF CARE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022-2030 (USD MILLION)
  • TABLE 175 CAMBODIA: ASEAN POINT OF CARE DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE TESTING PRODUCTS, BY TECHNOLOGY, 2022-2030 (USD MILLION)
  • TABLE 176 CAMBODIA: ASEAN POINT OF CARE DIAGNOSTICS MARKET, BY END USER, 2022-2030 (USD MILLION)
  • TABLE 177 LAOS: MACROECONOMIC INDICATORS FOR ASEAN POINT OF CARE DIAGNOSTICS MARKET
  • TABLE 178 LAOS: ASEAN POINT OF CARE DIAGNOSTICS MARKET, BY PRODUCT, 2022-2030 (USD MILLION)
  • TABLE 179 LAOS: ASEAN POINT OF CARE DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE TESTING PRODUCTS, BY DISEASE TYPE, 2022-2030 (USD MILLION)
  • TABLE 180 LAOS: ASEAN POINT OF CARE DIAGNOSTICS MARKET FOR RESPIRATORY INFECTION TESTING PRODUCTS, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 181 LAOS: ASEAN POINT OF CARE DIAGNOSTICS MARKET FOR HEPATITIS TESTING PRODUCTS, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 182 LAOS: ASEAN POINT OF CARE DIAGNOSTICS MARKET FOR GLUCOSE MONITORING PRODUCTS, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 183 LAOS: ASEAN POINT OF CARE DIAGNOSTICS MARKET FOR CARDIOMETABOLIC MONITORING PRODUCTS, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 184 LAOS: ASEAN POINT OF CARE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022-2030 (USD MILLION)
  • TABLE 185 LAOS: ASEAN POINT OF CARE DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE TESTING PRODUCTS, BY TECHNOLOGY, 2022-2030 (USD MILLION)
  • TABLE 186 LAOS: ASEAN POINT OF CARE DIAGNOSTICS MARKET, BY END USER, 2022-2030 (USD MILLION)
  • TABLE 187 BRUNEI: MACROECONOMIC INDICATORS FOR ASEAN POINT OF CARE DIAGNOSTICS MARKET
  • TABLE 188 BRUNEI: ASEAN POINT OF CARE DIAGNOSTICS MARKET, BY PRODUCT, 2022-2030 (USD MILLION)
  • TABLE 189 BRUNEI: ASEAN POINT OF CARE DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE TESTING PRODUCTS, BY DISEASE TYPE, 2022-2030 (USD MILLION)
  • TABLE 190 BRUNEI: ASEAN POINT OF CARE DIAGNOSTICS MARKET FOR RESPIRATORY INFECTION TESTING PRODUCTS, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 191 BRUNEI: ASEAN POINT OF CARE DIAGNOSTICS MARKET FOR HEPATITIS TESTING PRODUCTS, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 192 BRUNEI: ASEAN POINT OF CARE DIAGNOSTICS MARKET FOR GLUCOSE MONITORING PRODUCTS, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 193 BRUNEI: ASEAN POINT OF CARE DIAGNOSTICS MARKET FOR CARDIOMETABOLIC MONITORING PRODUCTS, BY TYPE, 2022-2030 (USD MILLION)
  • TABLE 194 BRUNEI: ASEAN POINT OF CARE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022-2030 (USD MILLION)
  • TABLE 195 BRUNEI: ASEAN POINT OF CARE DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE TESTING PRODUCTS, BY TECHNOLOGY, 2022-2030 (USD MILLION)
  • TABLE 196 BRUNEI: ASEAN POINT OF CARE DIAGNOSTICS MARKET, BY END USER, 2022-2030 (USD MILLION)
  • TABLE 197 OVERVIEW OF STRATEGIES DEPLOYED BY KEY COMPANIES IN ASEAN POINT OF CARE DIAGNOSTICS MARKET, JANUARY 2021-MARCH 2025
  • TABLE 198 ASEAN POINT OF CARE DIAGNOSTICS MARKET: DEGREE OF COMPETITION
  • TABLE 199 ASEAN POINT OF CARE DIAGNOSTICS MARKET: COUNTRY FOOTPRINT
  • TABLE 200 ASEAN POINT OF CARE DIAGNOSTICS MARKET: PRODUCT FOOTPRINT
  • TABLE 201 ASEAN POINT OF CARE DIAGNOSTICS MARKET: TECHNOLOGY FOOTPRINT
  • TABLE 202 ASEAN POINT OF CARE DIAGNOSTICS MARKET: DETAILED LIST OF KEY STARTUPS/SMES
  • TABLE 203 ASEAN POINT OF CARE DIAGNOSTICS MARKET: COMPETITIVE BENCHMARKING OF KEY STARTUPS/SMES, BY TECHNOLOGY
  • TABLE 204 ASEAN POINT OF CARE DIAGNOSTICS MARKET: COMPETITIVE BENCHMARKING OF KEY STARTUPS/SMES, BY COUNTRY
  • TABLE 205 ASEAN POINT OF CARE DIAGNOSTICS MARKET: PRODUCT LAUNCHES & APPROVALS, JANUARY 2021-MARCH 2025
  • TABLE 206 ASEAN POINT OF CARE DIAGNOSTICS MARKET: DEALS, JANUARY 2021-MARCH 2025
  • TABLE 207 ASEAN POINT OF CARE DIAGNOSTICS MARKET: EXPANSIONS, JANUARY 2021-MARCH 2025
  • TABLE 208 ABBOTT: COMPANY OVERVIEW
  • TABLE 209 ABBOTT: PRODUCTS OFFERED
  • TABLE 210 ABBOTT: PRODUCT APPROVALS, JANUARY 2021-MARCH 2025
  • TABLE 211 ABBOTT: DEALS, JANUARY 2021- MARCH 2025
  • TABLE 212 F. HOFFMANN-LA ROCHE LTD.: COMPANY OVERVIEW
  • TABLE 213 F. HOFFMANN-LA ROCHE LTD.: PRODUCTS OFFERED
  • TABLE 214 F. HOFFMANN-LA ROCHE LTD.: PRODUCT LAUNCHES & APPROVALS, JANUARY 2021-MARCH 2025
  • TABLE 215 F. HOFFMANN-LA ROCHE LTD.: DEALS, JANUARY 2021- MARCH 2025
  • TABLE 216 SIEMENS HEALTHINEERS AG: COMPANY OVERVIEW
  • TABLE 217 SIEMENS HEALTHINEERS AG: PRODUCTS OFFERED
  • TABLE 218 SIEMENS HEALTHINEERS AG: PRODUCT APPROVALS, JANUARY 2021-MARCH 2025
  • TABLE 219 SIEMENS HEALTHINEERS AG: DEALS, JANUARY 2021- MARCH 2025
  • TABLE 220 SIEMENS HEALTHINEERS AG: EXPANSIONS, JANUARY 2021- MARCH 2025
  • TABLE 221 SYSMEX CORPORATION: COMPANY OVERVIEW
  • TABLE 222 SYSMEX CORPORATION: PRODUCTS OFFERED
  • TABLE 223 SYSMEX CORPORATION: EXPANSIONS, JANUARY 2021-MARCH 2025
  • TABLE 224 DANAHER CORPORATION: COMPANY OVERVIEW
  • TABLE 225 DANAHER CORPORATION: PRODUCTS OFFERED
  • TABLE 226 BD: COMPANY OVERVIEW
  • TABLE 227 BD: PRODUCTS OFFERED
  • TABLE 228 BD: DEALS, JANUARY 2021-MARCH 2025
  • TABLE 229 BD: EXPANSIONS, JANUARY 2021-MARCH 2025
  • TABLE 230 QUIDELORTHO CORPORATION: COMPANY OVERVIEW
  • TABLE 231 QUIDELORTHO CORPORATION: PRODUCTS OFFERED
  • TABLE 232 QUIDELORTHO CORPORATION: PRODUCT APPROVALS, JANUARY 2021-MARCH 2025
  • TABLE 233 QUIDELORTHO CORPORATION: DEALS, JANUARY 2021-MARCH 2025
  • TABLE 234 QUIDELORTHO CORPORATION: EXPANSIONS, JANUARY 2021-MARCH 2025
  • TABLE 235 CARDINAL HEALTH: COMPANY OVERVIEW
  • TABLE 236 CARDINAL HEALTH: PRODUCTS OFFERED
  • TABLE 237 CARDINAL HEALTH: DEALS, JANUARY 2021-MARCH 2025
  • TABLE 238 CARDINAL HEALTH: EXPANSIONS, JANUARY 2021-MARCH 2025
  • TABLE 239 BIOMERIEUX: COMPANY OVERVIEW
  • TABLE 240 BIOMERIEUX: PRODUCTS OFFERED
  • TABLE 241 BIOMERIEUX: PRODUCT APPROVALS, JANUARY 2021-MARCH 2025
  • TABLE 242 BIOMERIEUX: DEALS, JANUARY 2021-MARCH 2025
  • TABLE 243 EKF DIAGNOSTICS HOLDINGS PLC: COMPANY OVERVIEW
  • TABLE 244 EKF DIAGNOSTICS HOLDINGS PLC: PRODUCTS OFFERED
  • TABLE 245 EKF DIAGNOSTICS HOLDINGS PLC: PRODUCT LAUNCHES, JANUARY 2021-MARCH 2025
  • TABLE 246 EKF DIAGNOSTICS HOLDINGS PLC: DEALS, JANUARY 2021-MARCH 2025
  • TABLE 247 EKF DIAGNOSTICS HOLDINGS PLC: EXPANSIONS, JANUARY 2021-MARCH 2025
  • TABLE 248 THERMO FISHER SCIENTIFIC INC.: COMPANY OVERVIEW
  • TABLE 249 THERMO FISHER SCIENTIFIC INC.: PRODUCTS OFFERED
  • TABLE 250 THERMO FISHER SCIENTIFIC INC.: PRODUCT LAUNCHES, JANUARY 2021-MARCH 2025
  • TABLE 251 THERMO FISHER SCIENTIFIC INC.: DEALS, JANUARY 2021-MARCH 2025
  • TABLE 252 ACCUBIOTECH CO., LTD.: COMPANY OVERVIEW
  • TABLE 253 ACCUBIOTECH CO., LTD.: PRODUCTS OFFERED
  • TABLE 254 ACCUBIOTECH CO., LTD.: PRODUCT APPROVALS, JANUARY 2021-MARCH 2025
  • TABLE 255 BIOSYNEX SA: COMPANY OVERVIEW
  • TABLE 256 SD BIOSENSOR, INC.: COMPANY OVERVIEW
  • TABLE 257 SEKISUI DIAGNOSTICS: COMPANY OVERVIEW
  • TABLE 258 WERFEN: COMPANY OVERVIEW
  • TABLE 259 TRINITY BIOTECH: COMPANY OVERVIEW
  • TABLE 260 PTS DIAGNOSTICS: COMPANY OVERVIEW
  • TABLE 261 LIFESCAN IP HOLDINGS, LLC: COMPANY OVERVIEW
  • TABLE 262 CTK BIOTECH, INC.: COMPANY OVERVIEW
  • TABLE 263 WONDFO: COMPANY OVERVIEW
  • TABLE 264 ARKRAY, INC.: COMPANY OVERVIEW
  • TABLE 265 XIAMEN BOSON BIOTECH CO., LTD.: COMPANY OVERVIEW
  • TABLE 266 CREDO DIAGNOSTICS BIOMEDICAL PTE. LTD.: COMPANY OVERVIEW
  • TABLE 267 ANBIO BIOTECHNOLOGY INC.: COMPANY OVERVIEW
  • TABLE 268 SG DIAGNOSTICS: COMPANY OVERVIEW

List of Figures

  • FIGURE 1 MARKETS COVERED & REGIONS CONSIDERED
  • FIGURE 2 ASEAN POINT OF CARE DIAGNOSTICS MARKET: RESEARCH DESIGN
  • FIGURE 3 ASEAN POINT OF CARE DIAGNOSTICS MARKET: KEY INDUSTRY INSIGHTS
  • FIGURE 4 BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY- AND DEMAND-SIDE PARTICIPANTS
  • FIGURE 5 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE AND DESIGNATION
  • FIGURE 6 BOTTOM-UP APPROACH: COMPANY REVENUE ESTIMATION APPROACH
  • FIGURE 7 CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS
  • FIGURE 8 ASEAN POINT OF CARE DIAGNOSTICS MARKET: TOP-DOWN APPROACH
  • FIGURE 9 ASEAN POINT OF CARE DIAGNOSTICS MARKET: DATA TRIANGULATION METHODOLOGY
  • FIGURE 10 ASEAN POINT OF CARE DIAGNOSTICS MARKET: RESEARCH ASSUMPTIONS
  • FIGURE 11 ASEAN POINT OF CARE DIAGNOSTICS MARKET, BY PRODUCT, 2025 VS. 2030 (USD MILLION)
  • FIGURE 12 ASEAN POINT OF CARE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2025 VS. 2030 (USD MILLION)
  • FIGURE 13 ASEAN POINT OF CARE DIAGNOSTICS MARKET, BY END USER, 2025 VS. 2030 (USD MILLION)
  • FIGURE 14 ASEAN POINT OF CARE DIAGNOSTICS MARKET, BY COUNTRY, 2025 VS. 2030 (USD MILLION)
  • FIGURE 15 RISING PREVALENCE OF INFECTIOUS DISEASES TO PROPEL MARKET
  • FIGURE 16 GLUCOSE MONITORING PRODUCTS SEGMENT TO DOMINATE MARKET DURING FORECAST PERIOD
  • FIGURE 17 BIOCHEMISTRY SEGMENT TO HOLD LARGEST MARKET SHARE TILL 2030
  • FIGURE 18 HOME CARE SETTINGS AND CLINICAL LABORATORIES TO ACCOUNT FOR MAJOR MARKET SHARES DURING FORECAST PERIOD
  • FIGURE 19 VIETNAM TO REGISTER HIGHEST GROWTH DURING FORECAST PERIOD
  • FIGURE 20 ASEAN POINT OF CARE DIAGNOSTICS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
  • FIGURE 21 ESTIMATES OF TB INCIDENCE FOR SOUTHEAST ASIA REGION, BY AGE GROUP AND GENDER (2023)
  • FIGURE 22 ASEAN POINT OF CARE DIAGNOSTICS MARKET: TRENDS/DISRUPTIONS IMPACTING CUSTOMERS' BUSINESSES
  • FIGURE 23 ASEAN POINT OF CARE DIAGNOSTICS MARKET: VALUE CHAIN ANALYSIS
  • FIGURE 24 ASEAN POINT OF CARE DIAGNOSTICS MARKET: SUPPLY CHAIN ANALYSIS
  • FIGURE 25 ASEAN POINT OF CARE DIAGNOSTICS MARKET: ECOSYSTEM ANALYSIS
  • FIGURE 26 INVESTMENT & FUNDING SCENARIO, 2021-2024
  • FIGURE 27 ASEAN POINT OF CARE DIAGNOSTICS MARKET: PATENT ANALYSIS, JANUARY 2014-DECEMBER 2024
  • FIGURE 28 ASEAN POINT OF CARE DIAGNOSTICS MARKET: PORTER'S FIVE FORCES ANALYSIS
  • FIGURE 29 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS, BY TECHNOLOGY
  • FIGURE 30 KEY BUYING CRITERIA, BY TECHNOLOGY
  • FIGURE 31 ASEAN POINT OF CARE DIAGNOSTICS MARKET: POTENTIAL OF AI
  • FIGURE 32 ASEAN: POINT OF CARE DIAGNOSTICS MARKET SNAPSHOT
  • FIGURE 33 REVENUE ANALYSIS OF KEY PLAYERS IN ASEAN POINT OF CARE DIAGNOSTICS MARKET, 2022-2024
  • FIGURE 34 MARKET SHARE ANALYSIS OF KEY PLAYERS IN ASEAN POINT OF CARE DIAGNOSTICS MARKET, 2024
  • FIGURE 35 ASEAN POINT OF CARE DIAGNOSTICS MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2024
  • FIGURE 36 ASEAN POINT OF CARE DIAGNOSTICS MARKET: COMPANY FOOTPRINT
  • FIGURE 37 ASEAN POINT OF CARE DIAGNOSTICS MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2024
  • FIGURE 38 EV/EBITDA OF KEY VENDORS, 2025
  • FIGURE 39 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF KEY VENDORS, 2025
  • FIGURE 40 ASEAN POINT OF CARE DIAGNOSTICS MARKET: BRAND/PRODUCT COMPARISON MATRIX
  • FIGURE 41 ABBOTT: COMPANY SNAPSHOT (2024)
  • FIGURE 42 F. HOFFMANN-LA ROCHE LTD.: COMPANY SNAPSHOT (2024)
  • FIGURE 43 SIEMENS HEALTHINEERS AG: COMPANY SNAPSHOT (2024)
  • FIGURE 44 SYSMEX CORPORATION: COMPANY SNAPSHOT (2023)
  • FIGURE 45 DANAHER CORPORATION: COMPANY SNAPSHOT (2024)
  • FIGURE 46 BD: COMPANY SNAPSHOT (2024)
  • FIGURE 47 QUIDELORTHO CORPORATION: COMPANY SNAPSHOT (2024)
  • FIGURE 48 CARDINAL HEALTH: COMPANY SNAPSHOT (2024)
  • FIGURE 49 BIOMERIEUX: COMPANY SNAPSHOT (2024)
  • FIGURE 50 EKF DIAGNOSTICS HOLDINGS PLC: COMPANY SNAPSHOT (2023)
  • FIGURE 51 THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT (2024)
Show more
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Contact Us +1-866-353-3335
Hi, how can we help?
Contact us!